SKIN ADVERSE EVENTS DURING DUAL AND TRIPLE THERAPY FOR HCV-RELATED CIRRHOSIS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

FEDERICO ALESSANDRO; SGAMBATO DOLORES; COTTICELLI GAETANO; GRAVINA ANTONIETTA GERARDA; DALLIO MARCELLO; BENEDUCE FILIPPO; RUOCCO ELEONORA; ROMANO MARCO; LOGUERCIO CARMELA

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2014 | Volume:14 | Issue:3 Page(s): 1-4

Download Full-Text

View:

311

Download:

329

Cites:

Information Journal Paper

Title

SKIN ADVERSE EVENTS DURING DUAL AND TRIPLE THERAPY FOR HCV-RELATED CIRRHOSIS

Author(s)

Keywords

LIVER CIRRHOSIS

TELAPREVIR

SKIN DISEASES

Abstract

Introduction: Dermatological adverse events are an existing concern during treatment of hepatitis C virus infection. Peginterferon/ribavirin treatment is associated with well-characterized dermatological lesions tending towards a uniform entity of dermatitis. New TELAPREVIR- or boceprevir-based triple-therapy has led to significant improvements in sustained virological response rates, although associated with an increase in cutaneous adverse events compared peginterferon/ribavirin alone.Case Presentation: We report a case of a patient who discontinued TELAPREVIR because of severe skin eruptions and who, during ribavirin and interferon treatment, after a period free of skin lesions, developed new dermatological lesions different than those experienced during TELAPREVIR treatment.Conclusions: Several adverse effects are associated to anti-HCV drugs, hence appropriate skin care management and follow-up are very important. A careful anamnesis before the initiation of triple therapy is necessary to identify previous dermatological diseases that could increase skin adverse effects incidence.

Cites

No record.

References

No record.

Cite

APA: Copy

FEDERICO, ALESSANDRO, SGAMBATO, DOLORES, COTTICELLI, GAETANO, GRAVINA, ANTONIETTA GERARDA, DALLIO, MARCELLO, BENEDUCE, FILIPPO, RUOCCO, ELEONORA, ROMANO, MARCO, & LOGUERCIO, CARMELA. (2014). SKIN ADVERSE EVENTS DURING DUAL AND TRIPLE THERAPY FOR HCV-RELATED CIRRHOSIS. HEPATITIS MONTHLY, 14(3), 1-4. SID. https://sid.ir/paper/306570/en

Vancouver: Copy

FEDERICO ALESSANDRO, SGAMBATO DOLORES, COTTICELLI GAETANO, GRAVINA ANTONIETTA GERARDA, DALLIO MARCELLO, BENEDUCE FILIPPO, RUOCCO ELEONORA, ROMANO MARCO, LOGUERCIO CARMELA. SKIN ADVERSE EVENTS DURING DUAL AND TRIPLE THERAPY FOR HCV-RELATED CIRRHOSIS. HEPATITIS MONTHLY[Internet]. 2014;14(3):1-4. Available from: https://sid.ir/paper/306570/en

IEEE: Copy

ALESSANDRO FEDERICO, DOLORES SGAMBATO, GAETANO COTTICELLI, ANTONIETTA GERARDA GRAVINA, MARCELLO DALLIO, FILIPPO BENEDUCE, ELEONORA RUOCCO, MARCO ROMANO, and CARMELA LOGUERCIO, “SKIN ADVERSE EVENTS DURING DUAL AND TRIPLE THERAPY FOR HCV-RELATED CIRRHOSIS,” HEPATITIS MONTHLY, vol. 14, no. 3, pp. 1–4, 2014, [Online]. Available: https://sid.ir/paper/306570/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops